Action CDTX CIDARA THERAPEUTICS, INC.
Ajouter à une liste
Pour utiliser cette fonction vous devez être client ou membre
ConnexionInscription

Communiqués Cidara Therapeutics, Inc.

Actions

CDTX

US1717572069

Marché Fermé - Nasdaq
Autres places de cotation
 22:00:00 15/07/2024 		Varia. 5j. Varia. 1 janv.
12,5 USD +8,89 % Graphique intraday de Cidara Therapeutics, Inc. +6,11 % -21,28 %
15/05 Cidara Therapeutics, Inc. annonce ses résultats pour le premier trimestre clos le 31 mars 2024 CI
25/04 Les plus fortes hausses du prémarché MT

Communiqués

Recherche
Voir les résultats
Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !
Inscription 100% Gratuite
CIDARA THERAPEUTICS REPORTS INDUCEMENT GRANT UNDER NASDAQ LISTING RULE 5635(4)
AQ
Cidara Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
AQ
Cidara Therapeutics to Present Preclinical Data on CD388 at ASM Microbe 2024 Conference
AQ
Cidara Therapeutics: Q1 Earnings Snapshot
AQ
Cidara Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results
AQ
Cidara Therapeutics Regains Compliance with Nasdaq Continued Listing Rules
AQ
CDTX INVESTOR NOTICE: ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages Cidara Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation - CDTX
PR
Cidara Therapeutics Announces Presentations Highlighting Phase 1 and Phase 2a Clinical Data on CD388 at ESCMID 2024
AQ
CDTX LOSS ALERT: ROSEN, A LEADING LAW FIRM, Encourages Cidara Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation – CDTX
BU
CIDARA THERAPEUTICS ANNOUNCES DIVESTITURE OF REZAFUNGIN TO MUNDIPHARMA TO FOCUS ON ADVANCING THE CLINICAL DEVELOPMENT OF CLOUDBREAK DFC PIPELINE
AQ
Cidara Therapeutics Reacquires Global Development and Commercial Rights to CD388 and Announces Private Placement Financing of $240 Million
AQ
Cidara Therapeutics Announces Divestiture of Rezafungin to Mundipharma* to Focus on Advancing the Clinical Development of Cloudbreak DFC Pipeline
AQ
Cidara Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results
AQ
Cidara Therapeutics Announces Receipt of Nasdaq Delinquency Notice
AQ
Cidara Therapeutics Announces Reverse Stock Split
AQ
Cidara Therapeutics Presents Promising New Data on Novel Drug-Fc Conjugate Candidates at the American Association for Cancer Research (AACR) Annual Meeting 2024
AQ
CIDARA THERAPEUTICS TO PRESENT PRECLINCAL DATA ON MULTIPLE NOVEL DRUG-FC CONJUGATE CANDIDATES AT AMERICAN ASSOCIATION FOR CANCER RESEARCH ANNUAL MEETING 2024
AQ
Cidara Therapeutics to Present Preclincal Data on Multiple Novel Drug-Fc Conjugate Candidates at American Association dor Cancer Research (AACR) Annual Meeting 2024
AQ
Cidara Therapeutics Receives $11.14 Million Milestone Payment Following European Approval of REZZAYO
AQ
Cidara Therapeutics Announces Approval of REZZAYO by the MHRA for the Treatment of Invasive Candidiasis in Adults
AQ
Aucun résultat pour cette recherche
Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Filtres

Rechercher

Date de publication

Depuis le

Jusqu'au

  1. Bourse
  2. Actions
  3. Action CDTX
  4. Actualités Cidara Therapeutics, Inc.
  5. Communiqués